Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROLONE vs SUSTAIRE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
FDA-approved for maintenance treatment of asthma in patients aged 6 years and older,FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults,Off-label: acute asthma exacerbations (as part of SMART therapy)
AEROLONE is not a recognized drug; no standard dosing available.
50 mg orally twice daily
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life of 8-12 hours in healthy adults; prolonged in renal impairment.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Budesonide: extensively metabolized in the liver via CYP3A4 to inactive metabolites; formoterol: partially metabolized via glucuronidation and O-demethylation, with minor CYP involvement.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Primarily renal excretion (80-90% unchanged); minor biliary/fecal elimination (10-20%).
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 95% bound to albumin.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
0.2-0.3 L/kg; indicates limited extravascular distribution primarily in plasma and interstitial fluid.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
Oral: 70-80% due to first-pass metabolism; intravenous: 100%.
No data; not applicable.
GFR 30-59 m L/min: 50 mg once daily; GFR 15-29 m L/min: 25 mg once daily; GFR <15 m L/min: not recommended
No data; not applicable.
Child-Pugh A: 50 mg twice daily; Child-Pugh B: 25 mg twice daily; Child-Pugh C: 12.5 mg once daily
No data; not applicable.
Weight-based: 0.5 mg/kg orally twice daily, max 25 mg per dose
No data; not applicable.
Age >65 years: initiate at 25 mg twice daily; monitor renal function
None
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. SUSTAIRE is contraindicated for use as primary therapy for acute asthma exacerbations. For asthma, use only as add-on therapy for patients not adequately controlled on low-to-medium dose inhaled corticosteroids (ICS) or whose disease severity warrants initiation of ICS and LABA.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
LABA-associated asthma-related death; cardiovascular effects (tachycardia, hypertension); paradoxical bronchospasm; hypokalemia; hyperglycemia; increased susceptibility to infections; adrenal insufficiency with systemic steroid withdrawal; acute asthma exacerbation management.
Hypersensitivity to arformoterol or any component of the formulation
Primary treatment of status asthmaticus or acute asthma exacerbations; severe hypersensitivity to any ingredient.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
No significant food interactions. Grapefruit or grapefruit juice may increase systemic exposure; avoid excessive consumption. No specific dietary restrictions required.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, hypotonia, and withdrawal syndrome with chronic use. Avoid use unless benefit outweighs risk.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Excreted in breast milk; M/P ratio approximately 0.24. Limited data suggests low infant dose (0.5-1% maternal weight-adjusted dose). Monitor infant for drowsiness and feeding difficulties. Consider risk-benefit.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
No standard dose adjustment recommended. Increased plasma volume may reduce drug levels; monitor clinical response. Avoid near term due to risk of neonatal depression. Use lowest effective dose for shortest duration.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
SUSTAIRE is an inhaled corticosteroid (ICS) used for maintenance treatment of asthma. It is not indicated for acute bronchospasm. Rinse mouth with water after each use to prevent oral candidiasis. Titrate to lowest effective dose to minimize systemic effects. Monitor for growth suppression in children and adrenal insufficiency during stress or prolonged use.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
Use SUSTAIRE regularly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking SUSTAIRE without consulting your doctor, even if you feel better.,Keep track of your symptoms and peak flow if advised.,Seek medical help if your rescue inhaler is not working or you need more puffs than usual.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROLONE vs SUSTAIRE, answered by our medical review team.
AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. SUSTAIRE is a Methylxanthine Bronchodilator that works by SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROLONE and SUSTAIRE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. The standard adult dose of SUSTAIRE is: 50 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROLONE and SUSTAIRE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. SUSTAIRE is classified as Category C. Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.